The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry

In August 2017, cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with hormone receptor positive (HR+), HER2 negative (HER2−) advanced breast cancer (ABC). This study evaluates the implementation of CDK4/6 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Meegdes, Marissa, Geurts, Sandra M. E., Erdkamp, Frans L. G., Dercksen, Marcus Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., van de Winkel, Linda M. H., Teeuwen, Nathalie J. A., de Boer, Maaike, Tjan‐Heijnen, Vivianne C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290870/
https://www.ncbi.nlm.nih.gov/pubmed/34460112
http://dx.doi.org/10.1002/ijc.33785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290870/
https://www.ncbi.nlm.nih.gov/pubmed/34460112
http://dx.doi.org/10.1002/ijc.33785

Ejemplares similares